» Articles » PMID: 38770273

Evaluating the Efficacy of Mesenchymal Stem Cells for Diabetic Neuropathy: A Systematic Review and Meta-analysis of Preclinical Studies

Overview
Date 2024 May 21
PMID 38770273
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetic neuropathy affects nearly half of all diabetics and poses a significant threat to public health. Recent preclinical studies suggest that mesenchymal stem cells (MSCs) may represent a promising solution for the treatment of diabetic neuropathy. However, an objective assessment of the preclinical effectiveness of MSCs is still pending. We conducted a comprehensive search of PubMed, Web of Science, Embase, and Cochrane library to identify preclinical studies that investigate the effects of MSCs on diabetic neuropathy up until 15 September 2023. Outcome indicators consisted of motor and sensory nerve conduction velocities, intra-epidermal nerve fiber density, sciatic nerve blood flow, capillary-to-muscle fiber ratio, neurotrophic factors, angiogenic factors and inflammatory cytokines. The literature review and meta-analysis were conducted independently by two researchers. 23 studies that met the inclusion criteria were included in this system review for qualitative and quantitative analysis. Pooled analyses indicated that MSCs exhibited an evident benefit in diabetic neuropathy in terms of motor (SMD = 2.16, 95% CI: 1.71-2.61) and sensory nerve conduction velocities (SMD = 2.93, 95% CI: 1.78-4.07), intra-epidermal nerve fiber density (SMD = 3.17, 95% CI: 2.28-4.07), sciatic nerve blood flow (SMD = 2.02, 95% CI: 1.37-2.66), and capillary-to-muscle fiber ratio (SMD = 2.28, 95% CI: 1.55 to 3.01, < 0.00001). Furthermore, after MSC therapy, the expressions of neurotrophic and angiogenic factors increased significantly in most studies, while the levels of inflammatory cytokines were significantly reduced. The relevance of this review relies on the fact that summarizes an extensive body of work entailing substantial preclinical evidence that supports the efficacy of MSCs in mitigating diabetic neuropathy. While MSCs emerge as a promising potential treatment for diabetic neuropathy, further research is essential to elucidate the underlying mechanisms and the best administration strategy for MSCs.

Citing Articles

Editorial: Mesenchymal and induced-pluripotent stem cells as models to study biological processes.

Ambele M, Miranda C Front Genet. 2024; 15:1439306.

PMID: 39119585 PMC: 11306129. DOI: 10.3389/fgene.2024.1439306.

References
1.
Kanada S, Makino E, Nakamura N, Miyabe M, Ito M, Hata M . Direct Comparison of Therapeutic Effects on Diabetic Polyneuropathy between Transplantation of Dental Pulp Stem Cells and Administration of Dental Pulp Stem Cell-Secreted Factors. Int J Mol Sci. 2020; 21(17). PMC: 7503871. DOI: 10.3390/ijms21176064. View

2.
Bin Abd Razak H, Corona K, Totlis T, Chan L, Salreta J, Sleiman O . Mesenchymal stem cell implantation provides short-term clinical improvement and satisfactory cartilage restoration in patients with knee osteoarthritis but the evidence is limited: a systematic review performed by the early-osteoarthritis group of.... Knee Surg Sports Traumatol Arthrosc. 2023; 31(12):5306-5318. PMC: 10719133. DOI: 10.1007/s00167-023-07575-w. View

3.
Kender Z, Jende J, Kurz F, Tsilingiris D, Schimpfle L, Sulaj A . Sciatic nerve fractional anisotropy and neurofilament light chain protein are related to sensorimotor deficit of the upper and lower limbs in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2023; 14:1046690. PMC: 10053786. DOI: 10.3389/fendo.2023.1046690. View

4.
Xie X, Song Q, Dai C, Cui S, Tang R, Li S . Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer's disease: a phase I/II clinical trial. Gen Psychiatr. 2023; 36(5):e101143. PMC: 10582850. DOI: 10.1136/gpsych-2023-101143. View

5.
Kaur M, Misra S, Swarnkar P, Patel P, Kurmi B, Gupta G . Understanding the role of hyperglycemia and the molecular mechanism associated with diabetic neuropathy and possible therapeutic strategies. Biochem Pharmacol. 2023; 215:115723. DOI: 10.1016/j.bcp.2023.115723. View